Sandoz Announces Plans To Further Strengthen Its Antibiotics Manufacturing Setup In Europe
Sandoz to invest €150M in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network
Sandoz, a Novartis division, today announces plans to further strengthen its European antibiotics manufacturing network by further expanding production capabilities in Kundl, Austria and in Palafolls, Spain. By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive on the global market.
Sandoz reveals antibiotic manufacturing expansion plans in Europe
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Sandoz plans $183m boost to antibiotics production in Europe
pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.
May 18, 2021 9:14am
Last year, Sandoz teamed up with the Austrian government to boost antibiotics manufacturing at its plant in Kundl, Austria (pictured above). (Novartis)
While much of the pharma industry has shifted its focus away from antibiotics, Novartis Sandoz unit is doing just the opposite and is charting next steps in a multi-year manufacturing upgrade in Europe.
The generics giant has drawn up plans to invest €150 million ($183.32 million) in facilities in Austria and Spain over the next three to five years. Sandoz also says it will phase out production of oral drug ingredients at a separate plant in Spain, which it plans to shutter in 2024. The move comes after the company teamed up with the Austrian government last year on antibiotics production and inked a $500 million deal for GlaxoSmithKline’s globetrotting cephalosporin business in February.